TickerTalks
Browse all tickers →
TickerTalks›$BIIB
BIBIIB

Biogen Inc.

$BIIB·$29B·Drug Manufacturers - General·Healthcare
$199.15+0.1%YTD+13.6%1Y+47.2%
Mentions · last 7 days
2026-07-04: 3 posts2026-07-05: 5 posts2026-07-06: 10 posts2026-07-07: 46 posts2026-07-08: 83 posts2026-07-09: 118 posts2026-07-10: 130 posts395
Price updated 13h ago·X counts updated 13h ago
BIBIIB
$BIIBBiogen Inc.
$199.15+0.12%395 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $BIIB, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersEvent coming upAI verdict · as of 2026-07-11

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Neurology-biotech incumbent with a stealthy $1B acquisition — 47% year-over-year run into July 29 earnings.

Biogen is one of the older US neuroscience-focused biotech incumbents — multiple sclerosis, Alzheimer's (Leqembi with Eisai), spinal muscular atrophy, and a maturing pipeline. The current chapter is a quiet compounder that has re-rated 47% year-over-year on Leqembi commercialization plus a fresh acquisition setup.

  • The Apellis acquisition adds real optionality: Biogen filed the pro-forma financials for its Apellis acquisition, and the $1B deal for a company that reportedly "won't say what it makes" points to a specific pipeline or platform tuck-in that the market is willing to give management the benefit of the doubt on.
  • Fundamentals are steady: revenue grew 2% year-over-year last quarter to $2.48B at a 73% gross margin and 16% operating margin — this is a fully-matured biotech, and 9% free-cash-flow yield at 21x TTM is a compounder multiple, not a story-stock premium.
  • The Q2 pre-announcement is the specific print signal: Biogen pre-announced ~$164M in acquired in-process R&D (IPR&D), upfront and milestone expense, worth roughly $0.95 in GAAP-and-non-GAAP EPS impact — the market is now pricing that in advance of the July 29 print, so the earnings-day gap has already partly happened.
  • The tape is stable: shares at the 79th percentile of the 52-week range, 11% above the 200-day moving average, with a 0.16 beta — a quality biotech compounder doing what it should.

The July 29 earnings is the fulcrum. Firm Leqembi revenue disclosure with clean underlying operating trends stripped from the IPR&D charge keeps the compounder framing intact. A soft Leqembi ramp or additional pipeline-related timing wobble turns event-ahead into a real cooling — near-ATH biotech compounders punish soft prints harder than the multiple would suggest.

What to watch: July 29 earnings — firm Leqembi revenue disclosure with clean underlying operating trends stripped from the IPR&D charge keeps the compounder framing intact; a soft Leqembi ramp or additional pipeline-related timing wobble turns event-ahead into a real cooling, and near-ATH biotechs punish soft prints harder.

On the calendar: 2026-07-29 — Q2 2026 earnings

no sentiment

Read the AI verdict + X sentiment for $BIIB

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $BIIB.

Drug Manufacturers - General · Healthcare

ETF up 2.7% today — structural driver intact: oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+18.2%YTD
+48.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
21.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
5.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
15.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
8.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
7.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
69.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 29, 2026$3.57$3.05+17.0%
Q4 2025Feb 6, 2026$1.99$1.63+22.1%
Q3 2025Oct 30, 2025$4.81$3.88+24.0%
Q2 2025Jul 31, 2025$5.47$3.90+40.3%
Next earningsWed, Jul 29·consensus EPS $3.17

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$2.5B+1.9%73.3%16.0%$2.17$696.7M
Q4 FY25$2.3B-7.1%78.2%-2.5%$-0.33$555.9M
Q3 FY25$2.5B-0.4%64.3%25.0%$3.18$1.2B
Q2 FY25$2.6B+7.3%64.2%22.2%$4.35$144.3M

Forward consensus

5-year forecast · up to 21 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$10.0B$9.7B – $10.1B$14.33$10.33 – $16.2920
FY27$10.2B$9.7B – $10.9B$16.32$10.84 – $19.4721
FY28$10.4B$10.3B – $10.5B$18.26$15.18 – $20.9718
FY29$10.7B$10.2B – $11.2B$19.63$18.44 – $20.8711
FY30$11.0B$10.5B – $11.6B$20.80$19.54 – $22.129

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.79%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+0.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+11.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 146.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.165-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyFeb 12Nicole MurphyHead of Pharm Ops and Tech3 sh$585SellFeb 9Priya SinghalHead of Development2.7K sh$532K
+ 30 other (19 awards · 6 exempts · 5 inkinds) in window

See when $BIIB insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
AI summary

Biogen held its 2026 Annual Meeting of Stockholders on June 9, 2026, with all ten director nominees elected for one-year terms through 2027. Most nominees received 100–121M 'for' votes, with Eric Rowinsky receiving the lowest support (~93.6M for) and Susan Langer the highest (~103.9M for). The meeting likely also addressed auditor ratification and compensation advisory votes, though those results are not shown in the excerpt. Standard governance event with no material impact.

SC 13D/AActivist amendmentMay 14SC 13D/A
AI summary

Biogen filed Amendment No. 1 to its Schedule 13D on Apellis Pharmaceuticals, Inc. as a final exit filing: Biogen now beneficially owns 0 shares (0.0%) of Apellis common stock, as all shares were irrevocably accepted for payment pursuant to the merger that closed May 14, 2026. This terminates Biogen's reporting obligation as a 5%+ holder of Apellis, which no longer exists as an independent public company following the acquisition. Procedural filing completing the Apellis/Biogen merger paper trail.

8-KMaterial agreementMay 148-K — Item 1.01: Material agreement · Item 2.01: Acquisition completed · Item 2.03: Material debt obligation · Item 7.01: Press release / Reg FD
AI summary

Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, consummating the Agreement and Plan of Merger dated March 31, 2026. In connection with the merger, Biogen, Apellis, and Equiniti Trust Company entered into a Contingent Value Rights (CVR) Agreement governing CVRs issued to former Apellis shareholders; Biogen's subsidiary irrevocably accepted all Apellis shares tendered. The deal is transformative for Biogen's pipeline, adding Apellis's complement-targeting franchise (notably SYFOVRE/pegcetacoplan in geographic atrophy and other complement-mediated diseases) at a cost reflected in the ~$164M Q2 IPR&D charge disclosed separately.

3New insider — initial holdingsApr 63
SC 13DActivist position (5%+)Apr 6SC 13D
8-KMaterial agreementMar 318-K — Item 1.01: Material agreement · Item 8.01: Other event
8-KOfficer or director changeMar 118-K — Item 5.02: Officer or director change
8-KOfficer or director changeFeb 118-K — Item 5.02: Officer or director change · Item 8.01: Other event
+ 24 other (6 earnings 8-Ks · 5 13Gs · 4 SC TO-Cs · 3 SC TO-T/As) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Why Biogen (BIIB) is Poised to Beat Earnings Estimates Againzacks.com·4d agoBiogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.fool.com·7d agoAmgen or Biogen: Which Biotech Stock Appears Better Poised?zacks.com·10d agoNew Strong Sell Stocks for June 30thzacks.com·11d agoBiotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highszacks.com·12d ago

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$NVO$PFE$ABBV$JNJ$MRK$GILD$AZN
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport